Nexilico is an early-stage computational biology startup focused on advancing microbiome and precision medicine research and development. The company specializes in developing next-generation predictive microbiome precision medicine technologies aimed at improving drug design, development, and clinical outcomes for a range of therapeutics. Nexilico operates within the biotechnology and healthcare sectors, serving pharmaceutical companies, research institutions, and healthcare providers. The business model revolves around leveraging its proprietary technologies to offer predictive analytics and insights that enhance the efficacy and safety of therapeutic interventions. Revenue is generated through partnerships, licensing agreements, and grants. Nexilico has been recognized for its innovative approach, receiving multiple Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF).

Keywords: computational biology, microbiome, precision medicine, predictive technologies, drug design, clinical outcomes, biotechnology, healthcare, SBIR grants, NIH, NSF.